SLC25A10 performs an oncogenic role in human osteosarcoma

Wang, Gaoyuan; Xia, Jianjun; Chen, Cheng; Qiu, Jie; Sun, P.H.; Peng, Zhiwei; Chen, Xiaoyu; Xu, Bin

doi:10.3892/ol.2020.11863

Cited by 9 publications

(8 citation statements)

References 46 publications

(67 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Solute carrier 25 family member 10 (SLC25A10), or dicarboxylate carrier, also is important for redox homeostasis. SLC25A10 levels are elevated in human osteosarcoma tissues, compared with normal bone tissues; higher SLC25A10 levels have also been positively correlated with metastization ( Wang et al, 2020 ).…”

Section: Oxidative Stress Mechanisms In Disease: How Is Bone Affectedmentioning

confidence: 99%

In Sickness and in Health: The Oxygen Reactive Species and the Bone

Reis

Ramos

2021

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Oxidative stress plays a central role in physiological and pathological bone conditions. Its role in signalment and control of bone cell population differentiation, activity, and fate is increasingly recognized. The possibilities of its use and manipulation with therapeutic goals are virtually unending. However, how redox balance interplays with the response to mechanical stimuli is yet to be fully understood. The present work summarizes current knowledge on these aspects, in an integrative and broad introductory perspective.

show abstract

Section: Oxidative Stress Mechanisms In Disease: How Is Bone Affectedmentioning

confidence: 99%

In Sickness and in Health: The Oxygen Reactive Species and the Bone

Reis

Ramos

2021

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

show abstract

“…SLC25A6 induces apoptosis in human HeLa and HepG2 cells [ 14 ]. SLC25A10 transports small metabolites by exchanging dicarboxylates for phosphate, sulfate, and other small molecules and functions as an oncogene in osteosarcoma [ 15 ], lung cancer, and breast cancers [ 16 ].…”

Section: Discussionmentioning

confidence: 99%

An integrated bioinformatic investigation of mitochondrial solute carrier family 25 (SLC25) in colon cancer followed by preliminary validation of member 5 (SLC25A5) in tumorigenesis

et al. 2022

View full text Add to dashboard Cite

Solute carrier family 25 (SLC25) encodes transport proteins at the inner mitochondrial membrane and functions as carriers for metabolites. Although SLC25 genetic variants correlate with human metabolic diseases, their roles in colon cancer remain unknown. Cases of colon cancer were retrieved from The Cancer Genome Atlas, and the transcriptionally differentially expressed members (DEMs) of SLC25 were identified. DNA level alterations, clinicopathological characteristics, and clinical survival were also investigated. A risk score model based on the DEMs was constructed to further evaluate their prognostic values in a clinical setting. The results were preliminarily validated using bioinformatic analysis of datasets from the Gene Expression Omnibus, immunohistochemical evaluations in clinical specimens, and functional experiments in colon cancer-derived cell lines. Thirty-seven DEMs were identified among 53 members of SLC25. Eight of 37 DEMs were introduced into a risk score model using integrated LASSO regression and multivariate Cox regression. Validated by GSE395282 and GSE175356, DEMs with high-risk scores were associated with the phenotypes of increasing tumor immune infiltration and decreasing glycolysis and apoptosis contents. SLC25A5 was downregulated in cancer, and its upregulation was related to better overall survival in patients from public datasets and in clinical cases. High SLC25A5 expression was an independent prognostic factor for 79 patients after surgical treatment. A negative correlation between CD8 and SLC25A5 was determined in specimens from 106 patients with advanced colon cancer. SLC25A5 attenuated cell proliferation, upregulated the expression of programmed cell death-related signatures, and exerted its biological function by inhibiting the MAPK signaling pathway. Our study reveals that mitochondrial SLC25 has prognostic value in patients with colon cancer. The bioinformatic analyses by following verification in situ and in vitro provide direction for further functional and mechanistic studies on the identified member of SLC25.

show abstract

“…In individuals with osteosarcoma, higher expression of SLC25A10 was associated with unfavorable clinicopathological characteristics. Functionally, SLC25A10 positively regulated cell proliferation through regulating the expression of Cyclin E1 (CCNE1), p21 and p27 ( Wang et al, 2020a ). However, the clinical significance of the SLC family genes in osteosarcoma needs to be further elucidated.…”

Section: Discussionmentioning

confidence: 99%

Identification of a Solute Carrier Family-Based Signature for Predicting Overall Survival in Osteosarcoma

2022

View full text Add to dashboard Cite

Given the important role of SLC family in essential physiological processes including nutrient uptake, ion transport, and waste removal, and that their dysregulation was found in distinct forms of cancer, here we identified a novel gene signature of SLC family for patient risk stratification in osteosarcoma. Gene expression data and relevant clinical materials of osteosarcoma samples were retrieved from The Cancer Genome Atlas (TCGA) database. Prognosis-related SLC genes were identified by performing univariate Cox regression analysis and were utilized to construct a four-SLC gene signature in osteosarcoma. It allowed patients to be classified into high- and low-risk groups, and Kaplan-Meier survival analysis in the training, testing, entire, and external GSE21257 cohorts suggested that the overall survival of patients in high-risk group was consistently worse than that in low-risk group, suggesting the promising accuracy and generalizability of the SLC-based signature in predicting the prognosis of patients with osteosarcoma. Moreover, univariate and multivariate Cox regression analyses indicated that the derived risk score was the only independent prognostic factor for osteosarcoma patients in TCGA and GSE21257 cohorts. Besides, a prognostic nomogram comprising the derived risk score and clinical features including gender and age was developed for clinical decision-making. Functional enrichment analyses of the differentially expressed genes between high- and low-risk group revealed that immune-related biological processes and pathways were significantly enriched. Estimation of tumor immune microenvironment using ESTIMATE algorithm revealed that patients with lower risk score had higher stromal, immune, and ESTIMATE score, and lower tumor purity. ssGSEA analyses indicated that the scores of various immune subpopulations including CD8+ T cells, DCs, and TIL were lower in high-risk group than these in low-risk group in both cohorts. As for the related immune functions, the scores of APC co-inhibition, CCR, check-point, T cell co-stimulation, and Type II IFN response were lower in high-risk group than these in low-risk group in both cohorts. In all, we identified a novel prognostic signature based on four SLC family genes that accurately predicted overall survival in osteosarcoma patients. Furthermore, the signature is linked to differences in immunological status and immune cell infiltrations in the tumor microenvironment.

show abstract

SLC25A10 performs an oncogenic role in human osteosarcoma

Cited by 9 publications

References 46 publications

In Sickness and in Health: The Oxygen Reactive Species and the Bone

In Sickness and in Health: The Oxygen Reactive Species and the Bone

An integrated bioinformatic investigation of mitochondrial solute carrier family 25 (SLC25) in colon cancer followed by preliminary validation of member 5 (SLC25A5) in tumorigenesis

Identification of a Solute Carrier Family-Based Signature for Predicting Overall Survival in Osteosarcoma

Contact Info

Product

Resources

About